Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome

Table 1

General characteristics of 48 patients treated with compound-QHP.

Group	Group A	Group B
Gender [/(%)]
Male	7 (29.2)	10 (41.7)
Female	17 (70.8)	14 (58.3)
Average age (years)	51.9 ± 16.7	52.4 ± 14.5
Karyotype risks
Very good/good	12 (50)	10 (41.67)
Intermediate	7 (29.17)	8 (33.33)
Poor/very poor	5 (20.84)	6 (25.0)
Diagnosis according to WHO [/(%)]
RA/RCMD/RARS	20 (83.3)	19 (79.2)
RAEB1	3 (12.5)	3 (12.5)
RAEB2	1 (4.2)	2 (8.4)
IPSS-R score [/(%)]
Very low/low	5 (23.8)	6 (25.0)
Intermediate	17 (70.8)	16 (66.7)
high/very high	2 (8.3)	2 (8.3)
The blood arsenic concentrations after one month of treatment (µg/L)	15.63 ± 3.83	16.31 ± 2.47